Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds

• US 7,582,648 B2
• Filed: 10/05/2006
• Issued: 09/01/2009
• Est. Priority Date: 07/30/2003
• Status: Active Grant

• Current Assignee: Rigel Pharmaceuticals, Inc.
• Original Assignee: Rigel Pharmaceuticals, Inc.
• Inventors: Keim, Holger, Argade, Ankush, Li, Hui, Singh, Rajinder
• Primary Examiner(s): Balasubramanian; Venkataraman
• Application Number:
  US11/539,142
• Publication Number:
  US 20080312438A1
• Time in Patent Office: 1,062 Days
• Field of Search: 544/323, 544/324, 514/275
• US Class Current: 514/275
• CPC Class Codes: A61K 31/506 not condensed and containing further heterocyclic rings
• CPC Class Codes: A61K 31/538 ortho- or peri-condensed with carbocyclic ring systems
• CPC Class Codes: A61K 31/541 Non-condensed thiazines containing further heterocyclic rings
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: C07D 403/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 403/14 containing three or more hetero rings
• CPC Class Codes: C07D 405/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 405/14 containing three or more hetero rings
• CPC Class Codes: C07D 413/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 413/14 containing three or more hetero rings
• CPC Class Codes: C07D 417/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 417/14 containing three or more hetero rings
• CPC Class Codes: C07D 498/02 in which the condensed system contains two hetero rings
• CPC Class Codes: C07D 498/04 Ortho-condensed systems
• CPC Class Codes: C07D 498/06 Peri-condensed systems

Abstract

The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.

Claims

1. A compound according to the structural formula:

2. The compound of claim 1, wherein R² is cyclohexyl optionally substituted with one or more of the same or different R⁸ groups.

3. The compound of claim 1, wherein R³⁵ is hydrogen.